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1. Introduction 
Chronic thromboembolic pulmonary hypertension (CTEPH) results from incomplete 
resolution of the vascular obstruction associated with pulmonary embolism (PE) (Fedullo et 
al., 2001; Hoeper et al., 2006). This condition is considered to develop in 1-4 % of patients 
who survive an acute pulmonary embolism (Becattini et al., 2006; Fedullo et al., 2001; Pengo 
et al., 2004). Given the worldwide incidence of acute PE, approximately 1:1000, this indicates 
that even in a small country like the Netherlands, CTEPH may be diagnosed in up to 600 
patients yearly.  
Most CTEPH patients present with gradually progressive exercise intolerance, typically 
portrayed as exertional dyspnea, fatigue, palpitations and/or on productive cough. In 
further stages of disease there may be signs of right ventricular failure, chest pain on 
exertion and syncope. The ensuing progressive right ventricular failure leads to progressive 
disability and early death ( Hoeper et al., 2004) .  
If left untreated, CTEPH is a progressive and life-threatening disorder; survival being 
proportional to the degree of pulmonary hypertension at diagnosis.  In CTEPH patients with a 
mean pulmonary arterial pressure (mPAP) above 30 mmHg at time of diagnosis, 5-years 
survival is about 30%, whereas in patients with a mPAP above 50 mmHg the 5-years survival 
may be as low as 10% (Lewczuk et al., 2001; Riedel et al., 1982). Pulmonary endarterectomy 
(PEA) is the therapy of first choice for CTEPH patients with surgical accessible thrombi 
(Fedullo et al., 2001; Jamieson et al., 2000, 2003). PEA has been found to improve, and in many 
cases normalize pulmonary hemodynamics, functional status and long-term survival. PEA, 
however, does not come without potential risk. Reported peri- and direct postoperative 
mortality still ranges between 4.4% and 16% even in experienced centres (Archibald et al., 
1999; Auger et al., 2007; Condliffe et al., 2008; Jamieson et al., 2000 ; Rubens et al., 2007). 
In this chapter we will discuss the pathophysiology of CTEPH. In particular, we will focus 
on the pathophysiology of the exercise limitation and dyspnea that is observed in these 
patients. Moreover, the effects of surgical treatment, that is the removal of the obstructing 
chronic thrombi by pulmonary endarterectomy, on cardiac function and the restoration of 
exercise tolerance and dyspnea will be discussed.  
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2. Pathophysiology of CTEPH 
Pulmonary hypertension (PH) in general is a progressive and life-threatening disorder. It is 
pathophysiologically characterized by a gradually progressive increase in the pulmonary 
vascular resistance. As a consequence, in order to maintain an adequate transpulmonary blood 
flow, the pulmonary artery pressure will increase. The definition of PH is based on right heart 
catheterisation measurements; and PH was classically defined as a mean pulmonary artery 
pressure (mPAP) greater than 25 mmHg at rest or 30 mmHg during exercise. Recently, 
however, inclusion of exercise-induced PH in the definition has been the subject of debate, 
leading to it´s exclusion from the most recent guidelines (Kovacs et al., 2009; Galie et al., 2009). 
In CTEPH, pulmonary hypertension is considered to be primarily the result of the anatomic 
loss of pulmonary vascular bed due to the irreversible chronic thromboembolic obstruction. 
However, the pathophysiology of the disease appears far more complex. Pneumonectomy, 
for instance, is associated with little, if any, increase in pulmonary artery pressure, even 
with follow-up to 11 years (Cournand et al., 1950; Smulders et al., 2007). Experimental 
studies have even indicated that up to a 75% reduction in lung volumes does not cause 
pulmonary hypertension (Harrison et al., 1957). Nevertheless significant pulmonary 
hypertension at rest can be observed in CTEPH patients with relatively minor chronic 
thromboembolic obstruction of the pulmonary vasculature (Jamieson et al., 2000). This 
indicates that factors other than simple hemodynamic consequences of redirected blood 
flow are likely to be involved in the pathophysiology of CTEPH.  
Concepts of pathogenesis and progression of the disease after the initial pulmonary embolus 
involve both recurrent thromboemboli and failure to resolve the acute thromboemboli. In the 
past, abnormalities in coagulation and fibrinolysis pathways have been identified in CTEPH 
patients, however, the frequency of these defects in such patients were similar to those in the 
general population. Lupus anticoagulant and antiphospholipid antibodies were shown to be 
present in 10-20% of patients with CTEPH, which is higher than in patients with acute venous 
thromboembolism (Auger et al., 1995; Wolf et al., 2000). Bonderman et al. showed increased 
levels of factor VIII (FVIII) in about 40% of CTEPH patients as compared to both healthy 
controls and patients with non-thromboembolic pulmonary hypertension (Bonderman et al., 
2003). FVIII is a well recognised risk factor for single (O'Donnell et al., 1997) and, in particular, 
recurrent venous thromboembolism (Kyrle et al., 2000). Furthermore, inherited deficiencies of 
protein C, protein S and anti-thrombin III were identified in 1-5% of patients (Colorio et al., 
2001; Moser et al., 1990). Moreover, other risk factors have been identified in the development 
of CTEPH, including chronic inflammatory disorders, myeloproliferative syndromes, 
ventriculo-atrial drains, a history of pacemaker infection, thyroid disease and replacement 
therapy, and splenectomy (Bonderman et al., 2005, 2009; Jais et al., 2005). 
Over time, a gradual hemodynamic and symptomatic decline can be observed in CTEPH 
patients. Progression of disease may be the consequence of recurrent thromboembolism or 
in situ pulmonary artery thrombosis. Hemodynamic progression, however, can also be 
observed in patients without evidence of recurrent thromboembolism, while using adequate 
oral anticoagulant treatment. Taken together, this indicates that  a second pathobiological 
process is likely to be involved (Lang, 2010). The current understanding is that a 
hemodynamically significant persistent obstruction of the pulmonary arteries may result in 
an elevated pulmonary artery pressure and high shear stress in areas which are spared from 
occlusion; this in combination with a concomitant inflammation, and an imbalance of 
vasoactive mediators may result in the vascular remodelling that is observed in these 
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patients (Bauer et al., 2002; Humbert et al., 2004 Humbert et al., 2004; Reesink et al., 2006; 
Hoeper et al., 2004; Lang, 2010). Histopathologic changes in the microvasculature, similar to 
those demonstrated in other forms of pulmonary arterial hypertension (PAH), were 
observed in lung biopsy specimens from CTEPH patients (Moser et al., 1973). The 
development of this slowly progressive secondary arteriopathy in the non-obstructed pre-
capillary pulmonary vessels is likely the cause of the progression of disease that can be 
observed in CTEPH patients (Fedullo et al., 2011; Hoeper et al., 2006; Lang, 2010). By 
contributing to the elevated pulmonary vascular resistance, this arteriopathy adversely 
affects cardiac function and may, in the end, contribute to the progressive hemodynamic 
instability and increased mortality observed in patients with CTEPH (Riedel et al., 1982).   
Advanced CTEPH leads to cardiac remodelling, as characterized by right ventricular (RV) 
dilatation and hypertrophy, tricuspid regurgitation and leftward ventricular septal bowing 
(LVSB), with a consequent impact on cardiac function (Fleg et al., 2000; Groepenhoff et al., 
2008; Kreitner et al., 2007, 2004; Reesink et al., 2007). We have shown that LVSB is present in 
the majority of CTEPH patients (Reesink et al., 2007). Early diastolic septal bowing is an 
ominous sign in patients with pulmonary hypertension. During systole, the pressure in left 
ventricle (LV) normally exceeds the RV pressure, showing a (positive) curvature away from 
the LV centre. During early LV diastole, the LV pressure drops to near zero to enable rapid LV 
filling. The increased RV pressure pushes the septum away from the from the RV centre, 
causing (negative) LVSB (Marcus et al., 2001). We have shown that the interventricular septal 
bowing correlates with the severity of pulmonary hypertension in CTEPH patients (Reesink et 
al., 2007). So, although RV dysfunction is most outspoken, also LV function is significantly 
impaired these patients. The impairment of the LV function might be attributable to 
ventricular interaction or ventricular interdependence (also known as the “reversed Bernheim 
phenomenon”): RV dilatation and hypertrophy shift the interventricular septum leftward, 
thereby causing decreased LV cavity size, contractility, compliance, and ejection fraction 
(Alpert et al., 2001). LV diastolic dysfunction, however, may also be caused in part by 
myocardial hypertrophy of the RV and interventricular septum, as documented in both 
patients with CTEPH and idiopathic pulmonary arterial hypertension (iPAH) (Hardziyenka et 
al., 2011; Marcus et al., 2001; Reesink et al., 2007). In iPAH, it was shown that ventricular 
interaction mediated by interventricular septum bowing caused an impairment of the LV 
filling and thereby contributed to the decreased stroke volume observed in these patients (Gan 
et al., 2006). We have recently shown that in (CTE)PH patients also atrophy of the LV free wall 
may contribute to the impairment of the LV function. In a rat model of right ventricular failure 
due to pulmonary hypertension, we showed that reduction in LV free wall mass can be, at 
least in part, explained by myocyte shrinkage due to atrophic remodelling associated with left 
ventricle underfilling (Hardziyenka et al., 2011). 
3. Pathophysiology of exercise limitation in CTEPH patients 
In CTEPH, as in pulmonary hypertension in general, exercise is primarily limited by the 
impairment of cardiac function. As discussed, advanced pulmonary hypertension in CTEPH 
leads to chronic RV volume overload, cardiac remodelling and dysfunction. The limitation 
in exercise capacity is in major part caused by the inability of the heart to sufficiently 
increase pulmonary blood flow due to a decreased RV stroke volume response during 
exercise (Raeside et al., 2000;  Holverda et al., 2006).  
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Normally, upon exercise cardiac output is elevated by increasing heart rate, stroke volume or 
both. When stroke volume increases, pulmonary blood flow will increase; pulmonary arterial 
pressure, however, will not significantly increase due to pulmonary vascular dilatation and 
recruitment (Bonderman et al., 2011).  In PH, however, these mechanisms of lowering 
pulmonary vascular resistance are lost due to the secondary arteriopathy in the pre-capillary 
pulmonary vessels. As a result, the pulmonary pressure will rise in order to maintain 
pulmonary blood flow with a subsequent effect on stroke volume upon exercise. The exercise-
associated increase in pulmonary arterial pressure will result in further impairment of RV 
function, as well as LV underfilling, both leading to a failing stroke volume response to 
exercise (Raeside et al., 2000). Stroke volume is determined by contractility and the end-
diastolic volume (EDV). Holverda and co-workers showed that the failure to increase SV upon 
exercise in iPAH patients was accompanied by a small increase in RV end diastolic volume 
(RVEDV) and a decrease in LV end diastolic volume (LVEDV) due to increased LVSB and RV 
forward failure hampering an adequate LV filling (Holverda et al., 2006).  Using  exercise 
studies during cardiac magnetic resonance imaging (cMRI) we found even a negative SV 
response, i.e. a decrease in SV upon exercise, in CTEPH patients; opposite from the response 
observed in healthy individuals. The observed maximal SV during exercise, thereby, 
correlated significantly with exercise capacity as expressed by peak oxygen consumption 
(V’O2-peak), as well as with the hemodynamic severity of disease at rest.  
Next to the decreased RV and LV function, responses related to ventilation-perfusion 
mismatching caused by the thromboembolic obstruction of the pulmonary vascular bed are 
also likely to play a significant role in the pathophysiology of the exercise limitation 
observed in CTEPH patients. (CTE)PH is associated with decreased ventilatory efficiency 
during exercise (D'Alonzo et al., 1987; Riley et al., 2000; Sun et al., 2001; Wasserman, 2004). 
As blood flow fails to perfuse the ventilated lung, dead space ventilation increases; to 
compensate for this increase in death space ventilation the patient’s ventilatory requirement 
must increase. At the same time, the inability to increase cardiac output impairs oxygen 
transport appropriately in response to exercise, causing a low work rate “lactic acidosis” 
and exercise-induced hypoxemia, thereby further stimulating the ventilatory drive. Similar 
to measures of decreased cardiac output, parameters of increased dead space ventilation, 
were found to be related to the hemodynamic severity of disease in PH patients (Raeside et 
al., 2000; Van der Plas et al., 2010; Sun et al., 2001; Yasunobu et al., 2005).   
The direct relation between exercise limitation and the hemodynamic severity of disease has 
lead to the use of (non-invasive) exercise testing for both prognostic and diagnostic 
information in (CTE)PH patients. The most commonly used test to study exercise tolerance 
in PH patients are the six minute walk test (6-MWT) and the symptom-limited cardio-
pulmonary exercise test (CPET).  
3.1 Exercise testing 
3.1.1 Six minute walk test 
The 6-MWT is by far the most popular and most frequently used exercise test in PH clinical 
practice and research. The 6-MWT is derived from the Cooper test, a 12 minute running test 
that was developed to evaluate fitness in healthy individuals (Cooper, 1968). The 6-MWT 
itself is a reproducible, inexpensive, safe, and simple exercise test that requires no exercise 
equipment or advanced training for technicians. The 6-MWT can be used to evaluate 
exercise limitation in patients with cardiac and pulmonary diseases (ATS guidelines, 2002). 
Walking is a daily life activity that can be performed by all but the most severely impaired 
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patients. The 6-MWT measures the distance walked on a flat, hard surface in a period of 6 
minutes; the 6-minute walk distance (6-MWD). It evaluates the global and integrated 
responses of all systems involved during exercise, i.e. the pulmonary and cardiovascular 
system, systemic and peripheral circulation, neuromuscular units and muscle cell metabolism. 
In contrast to CPET, however, it does not provide specific information on the function of each 
of the different organs and systems involved in exercise or on the mechanism of the exercise 
limitation. As the 6-MWT is a self-paced walking test (patients choose their own intensity of 
exercise and are allowed to stop and rest during the test), it assesses a sub-maximal level of 
functional capacity. Nevertheless, the 6-MWD has been found to correlate closely with 
maximal oxygen uptake in various pulmonary and cardiac diseases (Cahalin et al., 1996; Roul 
et al., 1998). In iPAH patients, the six-minute walk distance (6-MWD) was shown to correlate 
significantly with hemodynamic severity of disease (Miyamoto et al., 2000). Similarly, we 
demonstrated in 50 consecutive patients with CTEPH prior to PEA, that the 6-MWD decreases 
in proportion to New York Heart Association (NYHA) functional class, and correlated 
strongly with the hemodynamic severity of disease (Figure 1). Compared to the data in iPAH 
patients, in CTEPH patients, the observed correlations between 6-MWD and pulmonary 
hemodynamics appeared even more robust (Reesink et al., 2007). Therefore, the 6-MWD is 
considered a highly useful objective parameter to assess functional limitations and outcome 
after medical interventions in most CTEPH patients.     
 
 
 
Fig. 1. Correlations between the 6-MWD and the pulmonary hemodynamic parameters.  
Top right: Mixed SvO2; n = 46; Pearson r = 0.77; P < 0.0001. Top left: CO; Pearson r = 0.76;  
P < 0.0001 Bottom left: TPR; Pearson r = -0.75; P < 0.0001 Bottom right: mPAP; Pearson 
r = -0.62; P < 0.0001. mPAP, mean pulmonary artery pressure; 6-MWD, 6-minute walk 
distance; TPR, total pulmonary resistance; CO, cardiac output; SvO2, venous oxygen 
saturation. (Adapted from: Reesink  et al., 2007) 
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The decrease in 6-MWD in patients with CTEPH is assumed to result from reduced 
maximum aerobic capacity owing to the, already discussed, inability of the heart to increase 
pulmonary blood flow adequately upon exercise. In the severely impaired CTEPH patients 
(NYHA stage III and IV), the 6-MWD was shown to reflect maximum aerobic capacity. 
However, we reported an increasing difference between maximal aerobic capacity and the 
aerobic capacity attained during 6-MWT, with decreasing severity of disease. In mildly 
impaired PH patients (NYHA stage II), the 6-MWT did not reflect maximal aerobic capacity. 
This indicates that mildly impaired PH patients are limited in their 6-MWT for other reasons 
than their oxygen delivery capacity. Therefore, in this group of patients, the 6-MWD may 
not be an appropriate parameter to study outcome of medical interventions (Van der Plas et 
al., 2008). 
3.1.2 Cardio pulmonary exercise testing 
CPET is considered the gold standard for the evaluation of exercise intolerance in patients 
with pulmonary and cardiac disease, and is based on the principle that system failure 
typically occurs while the system is under physical stress (Palange et al., 2007). CPET is 
based on a symptom-limited incremental exercise protocol in combination with breath-by-
breath analysis of cardiopulmonary variables, such as oxygen consumption (V’O2), carbon 
dioxide output (V’CO2), minute ventilation (V’E), heart rate (HR) and arterial oxygen 
saturation. From these variables others can be calculated, like the oxygen pulse (O2-pulse; 
V’O2/HR) as derivative of stroke volume, and the ventilatory equivalent of CO2 
(V’E/V’CO2) as measure of ventilatory efficiency. As such, in contrast to the 6-MWT, CPET 
requires expensive equipment and well trained technicians. During CPET, workload is 
typically increased in a stepwise manner, depending on the predicted maximum exercise 
capacity of the patient; with the prerequisite that maximal effort should be attained in 10-15 
minutes. All patients are stimulated to exercise to their personal maximum exercise 
capability, allowing peak exercise capacity to be determined. As opposed to the 6-MWT, 
CPET not only evaluates the global and integrated responses of all the organ systems 
involved during exercise, it also provides specific information on the function of each of the 
different components determining the exercise capacity. Maximal exercise capacity is 
determined by the “weakest link” in the interdependent physiological components of the 
gas transport mechanisms (Wasserman et al., 2004).   
In PH, CPET has been shown to be a useful tool to assess the severity of disease and 
prognosis (Deboeck et al., 2004; Sun et al., 2001; Wensel et al., 2002; Yasunobu et al., 2005). 
CPET in patients with PH shows a distinct pattern of abnormal responses to exercise, with 
reductions in peak oxygen uptake (V’O2-peak), O2 pulse, V’O2 at the anaerobic threshold 
and an increase in V’E/V’CO2. This pattern is well validated and has prognostic significance 
in patients with pulmonary arterial hypertension (D'Alonzo, et al. 1987; Sun, et al. 2001; 
Wasserman et al., 2004). In CTEPH, most of the patients we studied had by definition a 
reduced exercise capacity with a decreased peak oxygen uptake (V’O2-peak), i.e. below 84% 
of the predicted value. On average, V’O2-peak and peak O2-pulse were decreased with 
increasing severity of PH (Figure 2). V’E/V’CO2 at anaerobic threshold was increased in 
almost all patients. V’O2-peak showed a significant inverse correlation with resting mean 
pulmonary arterial pressure and total pulmonary resistance (r=-0.625, p=0.007 and r=-0.676, 
p=0.003 respectively).  
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Fig. 2. Characteristic abnormalities of exercise parameters in CTEPH patients (n= 49) with 
mild PH (mPAP <30 mmHg), moderate PH (mPAP ≥ 30, ≤ 50 mmHg) or severe  
PH (> 50 mmHg). V’O2-peak = peak oxygen uptake. V’O2@AT = oxygen uptake at anaerobic 
threshold;  O2 –pulse = oxygen pulse;  V’E /V’CO2 = ventilation equivalent for carbon 
dioxide (unpublished data).  
4. Pathophysiology of dyspnea in CTEPH 
The one common presenting symptom in patients with CTEPH is dyspnea (Jamieson et al., 
2000; Viner et al., 1994). Dyspnea is associated with decreased exercise performance, 
functional status and quality of life (Wasserman, 2004). Dyspnea includes several 
qualitatively distinct sensations that can arise from different pathophysiological 
mechanisms. In general, it is considered to be the result of a complex interaction of signals 
originating within the central nervous system and a variety of signals from receptors in the 
upper airway, lungs and chest wall (Manning et al., 1995; Yasunobo et al., 1999). 
Dyspnea can be assessed by the NYHA functional classification and the Borg score. NYHA 
functional class is a doctor reported dyspnea scoring system that quantifies a patient’s level 
of exercise intolerance, expressing the patients (dis)ability to perform everyday activities. 
The Borg score, on the other hand, is a patient reported quantitative scaling method of the 
symptomatic dyspnea. Patients rate their own dyspnea on a scale from 0 (no dyspnea) to 10 
(absolutely breathlessness) (Borg, 1982). 
In CTEPH, dyspnea can be attributed to multiple factors: increased dead space ventilation, 
hypoxemia, sympathetic overstimulation and/or stimulation of pressure receptors in the 
pulmonary vascular bed may all give rise to an increased ventilatory demand (Manning et al., 
1995). This will contribute to an increase in respiratory motor output with a corresponding 
increase in the sense of effort, i.e. the work of breathing. Increased dead space ventilation, 
caused by ventilation-perfusion mismatching due to thromboembolic obstruction in the 
www.intechopen.com
 
Topics in Thoracic Surgery 
 
102 
vascular bed might be an attributable factor to the sensation of dyspnea in CTEPH patients 
(Sun et al., 2001). Dead space ventilation increases, as blood flow fails to perfuse the ventilated 
lung. To compensate for this increase in dead space ventilation the patient’s ventilatory 
requirement increases, leading to a sensation of dyspnea. Recently, we reported on this 
relation between dead space ventilation and the experienced dyspnea in fifty-four patients 
with CTEPH who underwent PEA (Van der Plas, et al. 2010). The dead space ventilation 
(VD/VT), as determined by the Bohr-Enghoff equation, was shown to be increased, and 
correlated significantly with the hemodynamic severity of disease as well as with patient-
reported sensations of dyspnea as assessed by the Borg score and NYHA functional class. 
Assessment of the expiratory end tidal PCO2 (PET,CO2) by capnography showed a significant 
lower PET,CO2 compared to the arterial PCO2 (Pa,CO2) (3.55 ± 0.43 vs. 4.46 ± 0.42 kPa, 
p<0.001), indicating a parallel origin of the observed dead space ventilation (Figure 3). 
 
 
Fig. 3. Model of parallel dead space ventilation. (Adapted from: Van der Plas et al., 2010) 
Even more, ventilation itself is stretched beyond the demands of the increased dead space, 
since patients were relatively hypocapnic, i.e. a Pa,CO2 below the clinical limit of 4.7 kPa. 
Moreover, Pa,CO2 correlated inversely with mPAP and TPR. The combination of alveolar 
hyperventilation and increased (parallel) dead space ventilation is remarkable as it puts an 
extra ventilatory drive on an already increased effort of breathing. These findings are in unison 
with reports in patients with iPAH (Meyer et al., 2005; Wessel et al., 1964; Zoia et al., 2002). The 
alveolar hyperventilation seemed to be only in part hypoxic driven, as administration of 100% 
oxygen for at least 20 minutes increased but did not normalize Pa,CO2 (4.50 ± 0.42 kPa vs. 4.58 
± 0.42 kPa). Increased sympathetic activity may play a causative role in the observed alveolar 
hyperventilation in our patients. Velez-Roa and colleagues found muscle sympathetic nerve 
activity (MSNA) to be elevated in patients with idiopathic and fenfluramine induced PAH 
(Velez-Roa et al., 2004). As with Pa,CO2 in our study, MSNA changed towards normal, but did 
not normalize by administration of hyperoxia. Increased sympathetic activation has been 
reported to increase ventilation (Jordan et al., 2000). The presence and cause of increased 
MSNA in patients with CTEPH and the relation between increased MSNA and alveolar 
hyperventilation might be subject of further research. 
5. Effects of surgical treatment by pulmonary endarterectomy 
5.1 Restoration of cardiac function 
Pulmonary endarterectomy, first reported in 1958 by Hurwitt and co-workers (Hurwitt et al., 
1958), remains the therapy of choice for patients with CTEPH and surgical accessible thrombi 
(Fedullo et al., 2011). PEA causes an instantaneous and permanent hemodynamic 
improvement (Corsico et al., 2008; D'Armini et al., 2007; Reesink et al., 2007), which is 
associated with an improvement in overall cardiac function already shortly after PEA.   
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The most widely used non-invasive tool in clinical practice to study RV dysfunction is 
echocardiography. In CTEPH, echocardiographically, restoration of overall RV function 
shortly after PEA was reported (Menzel et al., 2000; Menzel et al., 2002; Menzel et al., 2002). In 
fact, improvement of RV geometry and LV diastolic function after PEA was already reported 
by Dittrich and co-workers in 1988 and 1989 (Dittrich et al., 1988; Dittrich et al., 1989). In 
addition, reverse RV remodeling, that is improvement of RV dimensions and ejection fraction, 
was demonstrated in patients with iPAH after lung transplantation (Kasimir et al., 2004; Vizza 
et al., 1998). The usefulness of echocardiography in this respect, however, is somewhat limited 
due to its technical limitations (acoustic window) and the absence of a reliable mathematical 
assumption due to the complex geometry of the RV. In view of these limitations, cardiac MRI 
is considered a superior imaging technique to quantify the characteristics of RV function and 
morphology (Helbing et al., 1995; Mayer et al., 1996; Vogel et al., 1997). Using cMRI we and 
others have shown restoration of RV remodeling after hemodynamically successful PEA 
(Kreitner et al., 2007, 2004; Reesink et al., 2007). We studied the restoration of RV remodeling in 
CTEPH patients at least 4 months after PEA (Reesink et al., 2007). After PEA, RV end diastolic 
and systolic dimensions normalized; RV-SVI and RV-EF improved, but did not fully normalize 
compared to healthy controls. Also, RV hypertrophy (RV mass) decreased after PEA, but did 
not fully normalize in all patients. In addition, LVSB, preoperatively present in 15 of the 17 
patients studied, normalised after PEA. Moreover, the observed decrease in RV mass and 
change in LVSB correlated significantly with the observed postoperative hemodynamic 
improvement. Finally, after PEA, LV end-diastolic volume and the LV-EF, both decreased 
prior to PEA, normalized (Figure 4 and 5). Recently, Lino and co-workers studied the time 
course of the restoration of the RV remodeling and showed that it occurs early after PEA. In 
line with our observations, the parameters of RV remodeling did not fully normalize after a 6-
months follow-up period (Iino et al., 2008).   
 
 
Fig. 4. MRI short-axis cine images at basal (upper panel) and mid-ventricular (lower panel) 
level, before (A) and after (B) PEA (relative time 55% in the cardiac cycle). Note the 
encroachment of the interventricular septum into the LV before PEA and the restoration of 
the septal bowing to normal after PEA. Note also the reversal of RV hypertrophy and the 
normalization of the RV and LV volumes (Adapted from: Reesink et al., 2007) 
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Fig. 5. Left: Right ventricle mass  in patients with CTEPH (n = 17) before and after PEA 
compared with healthy controls (n = 12). Data are expressed as mean ± SEM. Right: Septal 
bowing (curvature: 1/R) in patients with CTEPH (n = 17) before and after PEA compared with 
healthy controls (n = 12). Data are expressed as mean ± SE (Adapted from Reesink et al., 2007) 
 
As already extensively discussed, RV dysfunction and LV dysfunction occur in CTEPH 
patients because both are closely interdependent (Hardziyenka et al., 2011). Decreased RV 
ejection fraction relates to decreased LV diastolic filling and this may induce LV atrophy. As 
mentioned, we have observed a significant lower LV free wall mass index as determined by 
cMRI in CTPEH patients with RV dysfunction. In these patients, after PEA restoration of the 
LV free wall mass to normal values was observed (Hardziyenka et al., 2011) Recently, we 
also have reported on our studies on the time course of the restoration of RV systolic and 
diastolic function after PEA by use of echocardiography (Surie et al., 2011). Two weeks after 
PEA RV afterload and dimensions had decreased significantly, without further 
improvement during follow-up. Global RV function, expressed by the myocardial 
performance index (MPI) (Tei et al., 1996), showed a gradual improvement during the 
follow-up period. In contrast, 2 weeks after PEA systolic RV function, as assessed by 
tricuspid annular plane systolic velocity excursion (TAPSE) (Forfia et al., 2006) (Figure 6) 
and peak tricuspid annular systolic velocity of the RV (Saxena et al., 2006), had worsened, 
with a subsequent incomplete restoration during follow-up. Also, the diastolic RV function, 
as determined by the tricuspid-to-annulus ratio (TDI E/E’) (Lim et al., 2009) (Figure 6) 
 
 
Fig. 6. Time course of restoration of diastolic (TDI E/E’; left) and systolic (TAPSE; right) RV 
function after PEA (Adapted from: Surie et al., 2011). 
showed a similar biphasic response. The observed perioperative dynamics of systolic and 
diastolic RV function after PEA are in line with studies in patients undergoing coronary 
artery bypass graft (CABG) surgery for coronary artery disease. The mechanism of the 
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isolated effect on systolic and diastolic RV function remains fully unclear; however, it does 
not appear solely related to the use of cardiopulmonary bypass (Unsworth et al., 2010). 
Ischemia, inflammation, and myocardial oedema have been suggested; it can be 
hypothesized that the hypertrophied and dilated RV in patients with CTEPH might be even 
more sensitive to ischaemia or other surgery-related injury.  
5.2 Restoration of exercise tolerance  
5.2.1 Restoration of stroke volume response  
Exercise tolerance in patients with CTEPH is limited by an inadequate RV stroke volume 
response upon exercise. As previously discussed, preoperatively, SV decreases during 
exercise in patients with CTEPH; moreover, SV during exercise is related to exercise 
capacity as expressed by V’O2-peak as well as the hemodynamic severity of disease. One 
year after PEA, we demonstrated restoration of the SV response: change upon exercise in 
SVI pre-PEA: -2.8 ± 4.6 ml/m2 vs. change upon exercise SVI post-PEA: 4.0 ± 4.9 ml.m2  
(p<0.001; Table 1). The restoration of the SV response was accompanied by an increase in 
exercise tolerance, and by restoration of cardiac remodelling as assessed by cMRI. However, 
postoperatively, in some preoperatively more severely affected patients we still observed a 
negative SV response during exercise, despite (near) normalization in pulmonary 
hemodynamics.  
 
 Controls Pre PEA Post PEA 
 Rest Exercise Rest Exercise Rest Exercise 
SVI, ml.m-2 46.6±7.6  57.9±11.8   35.9±7.4 #  33.0±9.0 *# 35.9±5.2 # 39.9±5.4 *‡ # 
HR, min-1 65±10  94±8  69±12 93±13 * 73±11 97±9.0   * 
CI, l. min-1.m-2 3.0±0.3  5.4±1.1  2.4±0.4 # 3.0±0.8  *# 2.6±0.5 3.8±0.5  *‡ # 
Table 1. Stroke volume index (SVI), heart rate (HR) and cardiac index (CI) values at rest and 
during sub-maximal exercise for healthy controls and CTEPH patients before and after PEA. 
Data are expressed as mean±SD. * p<0.05 compared to resting conditions, ‡ p<0.05 post PEA 
compared to pre PEA, # p<0.05 compared with healthy controls  (Van Kan et al., unpublished 
data). 
5.2.2 Six-minute walk test 
We systematically studied the effects of PEA on the restoration of exercise tolerance by the 
6-MWT, and assessed its relation with the hemodynamic improvement observed shortly 
after surgery. One year after PEA, the 6-MWD had increased significantly, and the change 
correlated with the observed hemodynamic improvement. Moreover, in patients with 
normalized pulmonary hemodynamics after PEA, the 6-MWD, expressed as percentage of 
the predicted value, even tended to normalize (Reesink et al., 2007).  
In addition, we studied the time course of the postoperative functional recovery of patients 
with CTEPH up to 5 years after PEA. Whereas NYHA functional class and sPAP improved 
within the first 3 months after PEA without further improvement, the 6-MWD showed a 
gradual improvement over a 2-year follow-up period. Interestingly, the dynamics of 
functional recovery parallel the observed time course of the restoration of RV systolic and 
diastolic function. Furthermore, patients with residual pulmonary hypertension after PEA 
showed a greater improvement in 6-MWD, despite their worse absolute outcome (Van der 
Plas et al., 2011).  
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The improvement observed in 6-MWD after PEA can be explained in major part by an 
increase in maximum aerobic capacity due to the restoration of the SV response upon 
exercise due to instantaneous decrease in right ventricle afterload. This is supported by our 
observations that the increase in 6-MWD upon PEA was not associated with a concomitant 
increase in heart rate; this implicates that PEA improves cardiac output by improving RV SV 
response and thereby decreasing the need for a chronotropic response. (Van der Plas et al., 
2010).  A second contributing factor appears decrease in dead space ventilation due to the 
restoration of pulmonary blood flow. The decrease in dead space ventilation was shown to 
be associated with an improvement of dyspnea symptoms upon exercise as ventilatory 
demand decreases (Van der Plas et al., 2010). Another factor, which has been suggested to 
attribute to the observed long-term improvement of 6-MWD after PEA, might be a long-
term restoration of secondary arteriopathy which accommodates greater blood flow and 
improves gas exchange (Thistlethwaite et al, 2011). 
5.2.3 Cardiopulmonary exercise testing 
In addition to the restoration of SV response during exercise assessed by cMRI, we also 
studied the restoration of exercise tolerance in CTEPH patients after PEA by use of CPET. 
Pre-operatively maximal SV, assessed by cMRI, during exercise correlated with V’O2–peak 
(r=0.688, p=0.002) and O2 –pulse (r=0.759, p<0.001), and exercise SV correlated inversely 
with mPAP (r=-0.719, p=0.001) and TPR (r=-0.656, p=0.001). 
After PEA, we observed a normalization in exercise capacity in 11 out of 13 patients studied. 
V’O2-peak, peak workload and peak O2-pulse increased significantly while peak HR and 
peak V’E remained unchanged. V’E /V’CO2 showed a significant decrease, but normalized in 
8 out of 13 patients only (Table 2). Changes in V’O2–peak from baseline to 1 year post PEA, 
correlated significant with the directly after PEA observed changes in mPAP.  
 
Exercise parameters Pre PEA Post PEA 
V’O2 –peak, (% predicted) 72.5 ± 13.0 99 ± 13* 
Peak workload, (% predicted) 71 ± 23 97 ± 30* 
O2 –pulse, (% predicted) 75 ± 13 95 ± 14* 
V’E /V’CO2 49.8 ± 11.2 32.7 ± 4.0* 
Peak HR, (% predicted) 91 ± 8 94 ± 10 
Peak V’E , (% predicted) 98 ± 19 92 ± 14 
Table 2. Data are expressed as mean±SD. V’O2 = oxygen uptake;  O2 –pulse = oxygen pulse;  
V’E = minute ventilation; V’E /V’CO2 = ventilation equivalent for carbon dioxide; HR = heart 
rate. * p<0.05 post PEA compared to pre PEA (Van Kan et al.,  unpublished data). 
5.3 Effects of pulmonary endarterectomy on dyspnea 
Dyspnea can be assessed by using NYHA functional classification and the patient reported 
Borg score. In a cohort of fifty-four consecutive CTEPH patients both NYHA functional class 
(Figure 9) and resting Borg scores (Figure 8) improved after PEA. The change after PEA in 
NYHA functional class and resting Borg scores were independently correlated with the 
changes observed in absolute dead space and dead space ventilation, as well as with the 
hemodynamic improvement.   
As we have shown, the increase in dead space ventilation in CTEPH patients is significantly 
correlated with the hemodynamic severity of disease. After PEA, dead space ventilation 
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decreases, and was shown to normalize in the majority of patients. Hence, although the 
primary objective of PEA is to lower the right ventricular afterload, normalization of dead 
space by surgical removal of chronic thromboembolism contributed significantly to the 
postoperative recovery of the symptomatic dyspnea. 
 
 
Fig. 8. Change in absolute dead space (Delta VD) and change in mean pulmonary arterial 
pressure (Delta mPAP) against changes in NYHA functional class (Delta NYHA) (Adapted 
from: Van der Plas et al., 2010). 
 
 
Fig. 9. Change in absolute dead space (Delta VD) and change in mean pulmonary arterial 
pressure (Delta mPAP) against changes in Borg score at rest (Delta Borg) (Adapted from: 
Van der Plas et al., 2010). 
6. Future research 
In this overview, at least one possibly important factor contributing to the exercise limitation 
observed in CTEPH patients has not been addressed. The main focus of our studies has been 
on the cardiac and ventilatory contributing components. However, recently a reduction in 
respiratory and peripheral muscle strength has been observed in patients with iPAH which 
may be a determinant of exercise performance as well (Bauer et al., 2007; de Man et al., 2009; 
Mainguy et al., 2010; Meyer et al., 2005). The underlying mechanisms responsible for muscle 
weakness in PH patients are not yet known. In COPD and chronic (left) heart failure 
multiple mechanisms have been suggested to be involved in reduced muscle strength; 
changes in muscle fibre type ratio, abnormal intracellular Ca2+ profile, impaired muscle 
perfusion, decreased number of mitochondria, decreased oxidative enzymes, electrolyte 
disturbance, steroid therapy, malnutrition, wasting and cardiac cachexia. Most of these 
mechanisms do not seem to apply in PH (Meyer et al., 2005). However, we observed an 
increase in body mass index (BMI) one year after PEA in patients with CTEPH; in 48 
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consecutive CTEPH patients the BMI increased from 29.7±5.6 preoperatively to 30.8±5.7 at 1 
year after surgery (p=0.001). Based upon this observation, it might be hypothesized that 
some form of preoperative malnutrition or wasting may occur in CTEPH patients despite 
their in itself normal BMI. In COPD and heart failure, weight loss and loss of fat-free mass 
were shown to be associated with systemic inflammation (Anker et al., 2002; Decramer et al., 
2001; Gosker et al., 2000; Anker et al., 2002; Decramer et al., 2001; Gosker et al., 2000). Langer 
and colleagues found that heart failure due to CTEPH also appears to generate a 
pronounced systemic inflammatory response with the release of pro-inflammatory and anti-
inflammatory cytokines; moreover, PEA resulted in the normalization of preoperatively 
elevated TNF-alpha levels (Langer et al., 2004). Future research should focus on the 
clarification of the possible relationship between exercise intolerance, muscle weakness and 
systemic inflammation induced wasting in (CTE)PH patients. CTEPH patients can serve as 
an excellent model for these studies, in which the effect of PEA on muscle strength, body 
composition and systemic inflammation, and the relationships in its changes can be studied. 
7. Conclusions  
CTEPH results from incomplete resolution of the vascular obstruction caused by pulmonary 
thromboembolism. Patients typically present themselves with gradually exercise 
intolerance, portrayed as exertional dyspnea. Exercise is primarily limited by the inability of 
the right ventricle to sufficiently increase pulmonary blood flow upon exercise. If left 
untreated, the increased resistance and pulmonary arterial pressure leads to progressive 
cardiac remodeling with consequent impact on cardiac function. In addition, in CTEPH 
dead space ventilation is increased due to the vascular obstruction; and dead space 
ventilation correlates to the patient’s experienced dyspnea.  
Pulmonary endarterectomy is the therapy of choice for patients with CTEPH and surgical 
accessible thrombi. PEA causes an instantaneous and permanent hemodynamic 
improvement, which is (over time) associated with a restoration of parameters of RV and LV 
remodeling and function. Exercise tolerance increases primarily due to the improvement in 
stroke volume response. However, full symptomatic recovery also seems to depend on 
normalisation of dead space ventilation due to the restoration of pulmonary blood flow as a 
result of the surgical removal of chronic thromboembolism. 
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